...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>International journal of rheumatology >Baseline Comorbidities in a Population-Based Cohort of Rheumatoid Arthritis Patients Receiving Biological Therapy: Data from the Australian Rheumatology Association Database
【24h】

Baseline Comorbidities in a Population-Based Cohort of Rheumatoid Arthritis Patients Receiving Biological Therapy: Data from the Australian Rheumatology Association Database

机译：类风湿关节炎患者接受生物治疗的人群中的基线合并症：来自澳大利亚风湿病协会数据库的数据

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Aims. To describe the baseline characteristics of an Australian population-based cohort of rheumatoid arthritis (RA) patients commencing biological therapy.Methods. Descriptive analysis from the Australian Rheumatology Association Database (ARAD).Results. Up to October 2006, there were 681 RA patients taking biologics enrolled in ARAD. Baseline data were available for 624 (72% female, mean (SD) age 57.0 (12.5) years). Of these, 59.5% reported at least one comorbid condition, most commonly hypertension (35.7%) and osteoporosis (30.4%); 61 (9.8%) had a history of malignancy (35 nonmelanoma skin, 5 breast, 4 bowel, 5 cervix, 3 melanoma, 3 prostate and 1 each of lip, lung, myeloma, testis, uterus, vagina). Self-reported infections within the previous 6 months were common (71.5%).Conclusions. History of comorbidities, including recent infections, is common among Australian RA patients commencing biologics, and 10% have a history of malignancy. This may impact future evaluations of health outcomes among this population, including attribution of adverse events of biologic therapy.
机译：目的描述澳大利亚开始类风湿关节炎的类风湿关节炎（RA）患者群体的基线特征。来自澳大利亚风湿病协会数据库（ARAD）的描述性分析结果。截至2006年10月，共有681名接受生物制剂的RA患者参加了ARAD。现有624位基线数据（72％女性，平均（SD）年龄57.0（12.5）岁）。在这些患者中，有59.5％的患者至少患有一种合并症，最常见的是高血压（35.7％）和骨质疏松症（30.4％）; 61（9.8％）具有恶性病史（35例非黑素瘤皮肤，5例乳房，4肠，5子宫颈，3例黑素瘤，3例前列腺癌，以及唇，肺，骨髓瘤，睾丸，子宫，阴道各1例）。前6个月内自我报告的感染很常见（71.5％）。在开始使用生物制剂的澳大利亚RA患者中，合并症的病史（包括最近的感染）是常见的，而且10％的患者有恶性病史。这可能会影响该人群未来健康结局的评估，包括生物疗法不良事件的归因。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号